Countdown to International Flavors (IFF) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts expect International Flavors (IFF) to post quarterly earnings of $0.78 per share in its upcoming report, which indicates a year-over-year increase of 8.3%. Revenues are expected to be $2.67 billion, down 1.4% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.With that in mind, let's delve into the average projections of some International Flavors metrics that are commonly tracked and projected by analysts on Wall Street.According to the collective judgment of analysts, 'Net Sales- Nourish' should come in at $1.37 billion. The estimate suggests a change of -1.6% year over year.Based on the collective assessment of analysts, 'Net sales- Scent' should arrive at $555.31 million. The estimate points to a change of -3.9% from the year-ago quarter.The consensus among analysts is that 'Net Sales- Pharma Solutions' will reach $206.76 million. The estimate indicates a change of +1.9% from the prior-year quarter.Analysts forecast 'Net Sales- Health & Biosciences' to reach $532.95 million. The estimate suggests a change of +0.9% year over year.The consensus estimate for 'Adjusted Operating EBITDA- Nourish' stands at $167.93 million. Compared to the current estimate, the company reported $165 million in the same quarter of the previous year.Analysts expect 'Adjusted Operating EBITDA- Pharma Solutions' to come in at $31.04 million. The estimate compares to the year-ago value of $26 million.Analysts' assessment points toward 'Adjusted Operating EBITDA- Scent' reaching $103.11 million. Compared to the current estimate, the company reported $108 million in the same quarter of the previous year.The collective assessment of analysts points to an estimated 'Adjusted Operating EBITDA- Health & Biosciences' of $150.64 million. The estimate compares to the year-ago value of $162 million.View all Key Company Metrics for International Flavors here>>>Over the past month, International Flavors shares have recorded returns of +0.6% versus the Zacks S&P 500 composite's +3.9% change. Based on its Zacks Rank #3 (Hold), IFF will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report International Flavors & Fragrances Inc. (IFF): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks